750 related articles for article (PubMed ID: 37046648)
21. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.
Singh DD; Lee HJ; Yadav DK
Front Pharmacol; 2022; 13():1089066. PubMed ID: 36578543
[TBL] [Abstract][Full Text] [Related]
22. Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates.
Yan Y; Li Q; Li J
Transl Breast Cancer Res; 2022; 3():18. PubMed ID: 38751515
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
24. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends.
Vega Cano KS; Marmolejo Castañeda DH; Escrivá-de-Romaní S; Saura C
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612047
[TBL] [Abstract][Full Text] [Related]
25. Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.
Ulrich L; Okines AFC
Breast Cancer (Dove Med Press); 2021; 13():361-381. PubMed ID: 34079368
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer.
O'Sullivan CC; Smith KL
Curr Breast Cancer Rep; 2014 Sep; 6(3):169-182. PubMed ID: 25285186
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
[TBL] [Abstract][Full Text] [Related]
28. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
29. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
30. Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer.
Hong J; Park YH
Ther Adv Med Oncol; 2022; 14():17588359221106564. PubMed ID: 35756967
[TBL] [Abstract][Full Text] [Related]
31. Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges.
Guidi L; Pellizzari G; Tarantino P; Valenza C; Curigliano G
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831473
[TBL] [Abstract][Full Text] [Related]
32. Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer.
File D; Curigliano G; Carey LA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32239987
[TBL] [Abstract][Full Text] [Related]
33. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Kreutzfeldt J; Rozeboom B; Dey N; De P
Am J Cancer Res; 2020; 10(4):1045-1067. PubMed ID: 32368385
[TBL] [Abstract][Full Text] [Related]
34. Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer.
Aapro M; Cardoso F; Curigliano G; Eniu A; Gligorov J; Harbeck N; Mueller A; Pagani O; Paluch-Shimon S; Senkus E; Thürlimann B; Zaman K
Breast; 2022 Dec; 66():145-156. PubMed ID: 36279803
[TBL] [Abstract][Full Text] [Related]
35. HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments.
Essadi I; Benbrahim Z; Kaakoua M; Reverdy T; Corbaux P; Freyer G
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980624
[TBL] [Abstract][Full Text] [Related]
36. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T
Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035
[TBL] [Abstract][Full Text] [Related]
38. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
39. How we treat patients with metastatic HER2-positive breast cancer.
Nader-Marta G; Martins-Branco D; de Azambuja E
ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
[TBL] [Abstract][Full Text] [Related]
40. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
